期刊文献+

多肽药物汇利心康对小鼠心肌肥大与肌球蛋白重链表达的影响 被引量:1

Effects of Polypeptide Drug Huilixinkang on Cardiac Hypertrophy and Expressions of Myosin Heavy Chain in Mice
原文传递
导出
摘要 目的探讨Gq蛋白羧基端模拟肽盐酸GCIP-27(汇利心康,HLXK)对去甲肾上腺素诱导的小鼠心肌肥大和肌球蛋白重链表达的影响。方法 60只小鼠,随机分为对照组、模型组、氯沙坦组、HLXK(10、30、90μg.kg-1)组,分别给予生理盐水、去甲肾上腺素1.5 mg.kg-1(ip,bid)、氯沙坦钾9 mg.kg-1(ig,qd)、HLXK(10、30、90μg.kg-1;ip,bid)。连续给药20 d后,称量小鼠体重、心脏质量、左心室质量,计算心脏质量指数和左心室质量指数。采用免疫组化法测定肌球蛋白重链(myosin heavychain,MHC)α、β在心肌组织中的表达情况。结果去甲肾上腺素可明显诱导小鼠心肌重构。氯沙坦、HLXK(30、90μg.kg-1;bid)能明显降低小鼠心脏质量指数和左心室质量指数,增加心肌组织中α-MHC的表达,降低β-MHC的表达。结论汇利心康能够有效防止小鼠发生心肌肥大,纠正心肌肥大过程中的肌球蛋白重链表达失衡。 OBJECTIVE To explore the effects of Huilixinkang(HLXK),a mimetic polypeptide of Gq protein carboxyl terminus,on myocardial hypertrophy and expressions of myosin heavy chain(MHC) in mice.METHODS Sixty mice were randomly divided into 6 groups,ie control,model,losartan and HLXK(10,30,90 μg·kg-1) groups;and administrated with normal saline,noradrenaline 1.5 mg·kg-1(ip,bid),losartan 9 mg·kg-1 and HLXK 10,30,90 μg·kg-1(ip,bid),respectively.After 20 days′ treatment,all the mice were killed,and the cardiac hypertrophy indexes including heart weight index and left ventricular mass index were measured.The expressions of α-MHC and β-MHC in myocardium were determined using immunohistochemistry technique.RESULTS Noradrenaline could induce cardiac hypertrophy in mice significantly.Losartan 9 mg·kg-1,HLXK(30,90 μg·kg-1) markedly decreased heart weight index and left ventricular mass index,elevated the expression of α-MHC and decreased the expression of β-MHC in myocardium.CONCLUSION HLXK can effectively prevent cardiac hypertrophy in mice,and balance the expression of myosin heavy chain in the process of myocardial hypertrophy.
出处 《中国药学杂志》 CAS CSCD 北大核心 2011年第20期1566-1569,共4页 Chinese Pharmaceutical Journal
基金 国家"重大新药创制"科技重大专项资助(2009ZX09103-052) 国家自然科学基金资助(30973524) 重庆市科技攻关项目资助(CSTC2009AB5034)
关键词 肽类药物 GTP结合蛋白 心肌肥大 肌球蛋白重链 polypeptide drug GTP-binding proteins cardiac hypertrophy myosin heavy chain
  • 相关文献

参考文献10

  • 1NAROLSKA N A, EIRAS S, VANLOON R B, et al. Myosin heavy chain composition and the economy of contraction in healthy and diseased human myocardium [ J ]. J Muscle Res Cell Motil,2005,26 (1) :39-48.
  • 2FREY N, KATUS H A, OLSON E N, et al, Hypertrophy of the heart: a new therapeutic target [ J]. Circulation, 2004, 109 (13) : 1580-1589.
  • 3TARONE G, LEMBO G. Molecular interplay between mechani- cal and humoral signalling in cardiac hypertrophy [ J ]. Trends Mol Med, 2003, 9(9):376-382.
  • 4周见至,李晓辉,张海港,唐渊,王小芹.Cloning and gene expression of G protein competitive inhibitory polypeptide and its prophylactic effects on myocardial hypertrophy in vitro[J].Acta Pharmacologica Sinica,2003,24(11):1108-1112. 被引量:2
  • 5ZHANG H G, LI X H, ZHOU J Z, et al. Gaq-Protein carboxyl terminus imitation polypeptide GCIP-27 attenuates cardiac hyper- trophy in vitro and in vivo [ J ]. Clin Exp Pharmacol Physiol, 2007, 34(12) : 1276-1281.
  • 6何燕,钟国强,王炎,涂荣会,汪道文.氢氯噻嗪和吲哒帕胺逆转自发性高血压大鼠心肌肥厚及对心肌中eNOS表达的影响[J].中国药理学通报,2006,22(10):1184-1187. 被引量:8
  • 7SABBAH H N, SHAROV V G, GUPTA R C, et al. Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical vent ricular containment [ J ]. Circ Res, 2003, 93 ( 11 ) : 1095-1101.
  • 8KIM S, IWAO H. Molecular and cellular mechanisms of angio- tension Ⅱ mediated cardiovascular and renal diseases[ J]. Phar- macol Rev, 2000, 52(1) :11-34.
  • 9HANG C T, YANG J, HAN P, et al. Chromatin regulation by Brgl underlies heart muscle development and disease [ J ]. Na- ture. 2010. 466(7302) : 62-67.
  • 10TSOPORIS J N, MARKS A, KAHN H J, et al. inhibition of norepinephrine-induced eardiac hypertrophy in s10013 transgenic mice[J]. J Clin Invest, 1998, 102(8): 1609-1616.

二级参考文献19

  • 1汪海,龙超良,贾国栋,何华美,解卫平,冯华松,胡刚,刘国树.盐酸埃他卡林对内皮素系统的影响[J].中国药理学通报,2005,21(1):33-38. 被引量:11
  • 2李晓林,丁延魁,黄新艳,魏立,朱东亚,李庆平.高血压大鼠肥厚心肌中BMAL1蛋白表达的研究[J].中国药理学通报,2005,21(7):811-815. 被引量:5
  • 3汪红仪,陈洁,徐华娥,陶金,李胜男.Urocortin舒张自发性高血压大鼠胸主动脉与NO和K^+通道的关系[J].中国药理学通报,2005,21(10):1242-1245. 被引量:3
  • 4Zolk O, Kouchi I, Schnabel P, Bohm M. Heterotrimeric G proteins in heart disease. Can J Physiol Pharmacol 2000; 78:187-98.
  • 5Schnabel P, Bohm M. Heterotrimeric G proteins in heart disease. Cell Signal 1996; 8: 413-23.
  • 6Walter JK, Carmelo AM, Robert JL. Transgenic manipulation of myocardial G protein-coupled receptors and receptor kinases. Circ Res 1996; 78: 511-6.
  • 7Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, Allen LF, et al. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 1994;91: 10109-13.
  • 8Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor.Science 1994; 264: 582-6.
  • 9Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor.Science 1995; 268: 1350-3.
  • 10Shahab AA, Louis ML, Howard AR, Guido I, Robert JL,Walter JK. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998; 280: 574-7.

共引文献8

同被引文献7

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部